May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Electroretinogram Changes after Intravitreal Bevacizuamb for Retinopathy of Prematurity
Author Affiliations & Notes
  • M. A. Martinez-Castellanos
    Retina and Vitreous, APEC, Mexico, Mexico
  • H. Quiroz-Mercado
    Retina and Vitreous, APEC, Mexico, Mexico
  • A. Drack
    Rocky Mountain Lions Eye Institute University of Colorado, Denver, Colorado
  • G. Garcia-Aguirre
    Retina and Vitreous, APEC, Mexico, Mexico
  • J. L. Guerrero-Naranjo
    Retina and Vitreous, APEC, Mexico, Mexico
  • J. M. Jimenez-Sierra
    Retina and Vitreous, APEC, Mexico, Mexico
  • Footnotes
    Commercial Relationships  M.A. Martinez-Castellanos, None; H. Quiroz-Mercado, None; A. Drack, None; G. Garcia-Aguirre, None; J.L. Guerrero-Naranjo, None; J.M. Jimenez-Sierra, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4580. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. A. Martinez-Castellanos, H. Quiroz-Mercado, A. Drack, G. Garcia-Aguirre, J. L. Guerrero-Naranjo, J. M. Jimenez-Sierra; Electroretinogram Changes after Intravitreal Bevacizuamb for Retinopathy of Prematurity. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4580.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : The purpose of this study was to evaluate the electric response of the retina by standard electroretinogram to asses the retinal function after intravitreal bevacizumab in pediatric patients that were treated two years ago with antiangiogenic therapy for retinopathy of prematurity(ROP) stages III, IVa and IVb

Methods: : After a multicenter study of 53 eyes with ROP previosly published ( Invest Ophthalmol Vis Sci 2007; 48: E-Abstract 85), two years later we randomly choose 6 eyes from three patients of the 3 different groups. Group 1- patients treated with cryotherapy or laser that had persistence of neovascularization and progression of the disease. Group 2-patients with vitreous hemorrhage or persistence of fetal vasculature where we could not apply laser or cryo due to poor visualization of the retina. Group 3- Pre threshold or threshold disease. After Ethics committee Board Informed consent approval form parents, under oral sedation we performed standard electroretinogram recording rod response, scotopic maximal response, oscillatory potentials, single-flash cone response, and 30-Hz flicker response. We performed an analysis of our results

Results: : Two eyes classified as IVb that progressed to retinal detachment (RD) with subsequent successful reattachment after surgery had abnormal ERG of scotopic responce probably after cryotherapy. One of eyes with IVa the retina reattached completely after bevacizuamb treatment and other remained with minimal RD with decreased response in electroretinogram in scotopic response. In stage III we found a normal response

Conclusions: : The treatment of retinopathy of prematurity with bevacizumab is a promising therapy for a blinding disease. It is a concern the use of this therapy of this drug in immature retinas, but this study shows that the retina electric function is preserved, and bevacizumab may not be toxic for the retina

Clinical Trial: : NCT00346814

Keywords: retinal neovascularization • electroretinography: clinical • retinopathy of prematurity 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.